Neil Unmack

Novo Nordisk premium will survive drug wars

ECB's MPS kid gloves are a necessary evil

Assault on UK privilege has many possible targets

French foray into Italian mobile will be hard slog

Italy first to exploit EU's new-found weakness

Italy best to avoid sneaky bank bailout

How Europe can contain damage from Brexit

Greek deal is rational, predictable, messy

Sanofi bidding war looks expensive from the start

CoCos can work, but the fix will be painful

When Mario Draghi buys, it's time to sell

Berlusconi, Bollore, Murdoch lock horns: who wins?

Italy ends up on wrong side of oil punt

Safe havens scarce in brewing high-yield storm

More Carney sounds better for BoE than for him

AstraZeneca's M&A flurry clears value hurdle

Europe's least bad option: ditch Schengen

Mediobanca gets Barclays to pay for its own pivot

Pfizer-Allergan gets no support from scaredy arbs

Bollore's tilt at Telecom Italia board is too cheeky